A major Alzheimer’s risk gene may shrink brain cells years before symptoms

Millions of individuals worldwide carry APOE4, widely recognized by the scientific community as the single strongest genetic risk factor for the development of late-onset Alzheimer’s disease. Despite its prevalence—affecting approximately one in every four people and appearing in up to 75 percent of all clinical Alzheimer’s cases—the exact biological mechanisms by which this gene variant inflicts neurological damage have long remained elusive. Now, a pioneering study conducted by researchers at the Gladstone Institutes and published in the peer-reviewed journal Nature Aging sheds new light on this genetic vulnerability. The research maps out a previously unknown molecular pathway through which APOE4 begins altering brain activity and structure decades before any clinical symptoms or memory deficits become noticeable. More importantly, the investigative team successfully reversed these cellular abnormalities in animal models, offering a promising new avenue for therapeutic intervention.

Main Facts and Core Findings

The multi-year study centers on the discovery that APOE4 drives the excessive production of a specific protein known as Nell2, which in turn causes critical memory-processing neurons to shrink and exhibit abnormal hyperactivity. By closely analyzing murine models, the research team established a direct correlation: younger mice exhibiting the most pronounced brain hyperactivity eventually developed the most severe cognitive and spatial memory impairments as they aged.

Crucially, when the scientists experimentally reduced the production of Nell2 in adult mice carrying the APOE4 variant, the affected neurons returned to their normal size and regained healthy firing behaviors. This pivotal finding strongly suggests that the cellular damage inflicted by APOE4 is not necessarily permanent. It raises the exciting possibility that future pharmacological treatments targeting the Nell2 pathway could successfully protect or restore neurological function in human carriers who face a heightened genetic risk of developing Alzheimer’s disease.

Chronology and Evolution of APOE4 Research

To understand the magnitude of this recent breakthrough, it is helpful to examine the historical trajectory of Alzheimer’s genetics and neuroimaging research.

The APOE (apolipoprotein E) gene comes in three common polymorphic alleles: APOE2, APOE3, and APOE4. While APOE2 appears to confer a protective effect against the disease and APOE3 is considered neutral, APOE4 drastically increases susceptibility and often lowers the age of clinical onset. For decades, epidemiologists and geneticists have tracked these statistical correlations, noting that carrying a single copy of APOE4 roughly triples the risk of developing Alzheimer’s, while inheriting two copies increases that risk tenfold or more.

In the years leading up to the Gladstone Institutes study, human neuroimaging and electrophysiological studies began identifying curious anomalies. Researchers observed signs of unusually elevated brain activity—particularly within the hippocampus, a brain structure fundamental to learning and memory—in young, healthy human APOE4 carriers long before they reached middle age. While scientists hypothesized that this early neuronal hyperactivity contributed to subsequent cognitive decline, the underlying cellular mechanisms remained a mystery.

The Gladstone study bridges this historical gap. By utilizing advanced cellular recording techniques and molecular mapping in mice across different life stages, the team demonstrated that APOE4 fundamentally alters neural circuitry during youth. Unlike previous assumptions that blamed supporting glial cells, this study proved that the hyperactivity originates from the expression of APOE4 within the neurons themselves. Furthermore, while neurons in control mice with the protective APOE3 variant eventually grew more excitable, this shift only occurred during advanced old age. This timeline indicates that APOE4 essentially accelerates a normal aging process, pushing the brain onto an accelerated trajectory toward neurodegeneration.

Supporting Data and Methodological Approach

The rigor of the Gladstone Institutes study lies in its multi-layered methodology, combining high-resolution cellular recordings, single-cell gene expression profiling, and advanced genetic manipulation techniques.

To trace the origins of the anomaly, researchers recorded brain activity in young mice and examined individual neurons isolated from the hippocampus. The data revealed that young APOE4-carrying mice exhibited excessive neuronal firing in specific subregions of the hippocampus—the exact anatomical areas that consistently show hyperactivity in human APOE4 carriers. Statistical analysis of the behavioral trials confirmed a predictive link: the severity of neuronal hyperactivity in young mice directly correlated with poor performance on spatial learning and memory tests later in life.

Seeking the molecular culprit behind this dysfunction, the research team conducted a comprehensive gene expression analysis across various cell types within the hippocampus. This high-resolution screening highlighted Nell2 as a significant outlier, with expression levels markedly elevated in APOE4 neurons.

To test whether Nell2 was merely a byproduct or the actual driver of the pathology, the scientists deployed CRISPR interference (CRISPRi), a molecular tool designed to suppress gene activity without permanently altering the host organism’s DNA. By applying CRISPRi to reduce Nell2 levels in adult mice carrying APOE4, the researchers observed a physical and functional normalization of the cells. The shrunken neurons expanded back to their normal physiological dimensions, and their hyperactive firing patterns subsided into healthy baseline rhythms.

Official Responses and Expert Analysis

The implications of these findings have resonated strongly throughout the global neuroscience community. Principal staff research scientist Dr. Misha Zilberter, a senior author of the study at Gladstone, emphasized the novelty and precision of the investigation.

"To the best of our knowledge, this is the first study that has directly examined what APOE4 does to the function of neurons at different ages," Dr. Zilberter stated. "We found fundamental changes in brain circuits occurring in young mice that still had normal learning and memory, and importantly, that those changes predicted the development of cognitive deficits at older ages."

Dr. Zilberter also highlighted the paradigm-shifting discovery regarding the cellular source of the risk. While conventional wisdom heavily implicated astrocytes—the star-shaped support cells in the brain that produce the vast majority of APOE—experimental deletions revealed a different reality. "When we deleted the APOE4 gene from astrocytes, nothing changed," Dr. Zilberter noted. "But when we deleted it from neurons, the cells became larger and started functioning normally again."

Dr. Yadong Huang, associate director of the Gladstone Institute of Neurological Disease and co-senior author of the study, underscored the broader translational potential for human medicine. "This study is a big breakthrough for the field of Alzheimer’s research," Dr. Huang remarked. "It opens the door to a better understanding of how APOE4 alters the function of neurons at a young age to increase risk of cognitive decline, and to the development of therapies that could block the detrimental effects of APOE4 early on."

Reflecting on the reversibility of the phenotype, Dr. Huang added, "What’s exciting about Nell2 is that we were able to reverse the disease manifestations in adult mice by lowering its level. That tells us the damage is not irreversible, and that there may be a window for intervention even after disease processes have been triggered."

First author Dr. Dennis Tabuena, a scientist co-mentored by Zilberter and Huang, reinforced the predictive power of the animal models. "We found that the extent of hyperactivity in young mice predicted how poorly they performed on spatial learning and memory tests later in life," Dr. Tabuena explained, validating the timeline from early cellular stress to eventual cognitive failure.

Broader Impact and Future Implications for Alzheimer’s Therapeutics

The publication of this study arrives at a critical juncture in the fight against Alzheimer’s disease. For decades, therapeutic pipelines have focused heavily on clearing amyloid-beta plaques and tau tangles—pathological hallmarks that typically appear late in the disease progression, often after significant and irreversible neural destruction has already occurred.

By shifting the focus upstream to early neuronal dysfunction and developmental pacing, the Gladstone findings point toward a preventive paradigm. Identifying Nell2 as a druggable target provides pharmaceutical researchers with a specific molecular pathway to interrupt before clinical symptoms manifest. Because the study demonstrated that lowering Nell2 in adult mice successfully reversed abnormal neuronal activity, future therapies may not only prevent disease onset in high-risk individuals but also ameliorate existing cellular dysfunction in early-stage patients.

Funding for this foundational research was provided by a robust consortium of federal and institutional grants, primarily led by the National Institute on Aging, alongside contributions from the National Institute of Neurological Disorders and Stroke and the National Center for Research Resources. As translational research progresses from murine models toward human clinical applications, studies of this caliber pave the way for a future where genetic predispositions like APOE4 can be intercepted, neutralizing Alzheimer’s risk before the disease ever has the chance to take hold.